Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002036 | Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human) | PHASE1 | COMPLETED | 12 | — | — | - | - | Feb 20, 2009 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Anti-HIV Immune Serum Globulin (Human) | DRUG | - |
Inclusion Criteria Patients must have: * Proof of HIV infection. * Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or \> 3 months of AZT therapy. Exclusion Criteria Co-existing Condition:...